Charles River Laboratories Intl. (CRL) Posts Quarterly Earnings Results, Beats Estimates By $0.14 EPS

Charles River Laboratories Intl. (NYSE:CRL) released its quarterly earnings data on Tuesday. The medical research company reported $1.40 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.26 by $0.14, Bloomberg Earnings reports. Charles River Laboratories Intl. had a return on equity of 26.58% and a net margin of 10.72%. The company had revenue of $478.50 million during the quarter, compared to the consensus estimate of $475.02 million. During the same quarter in the prior year, the firm posted $1.21 earnings per share. The firm’s revenue was up 2.5% compared to the same quarter last year.

Shares of Charles River Laboratories Intl. (CRL) opened at $108.00 on Wednesday. The firm has a market cap of $4,830.40, a P/E ratio of 26.34, a price-to-earnings-growth ratio of 1.50 and a beta of 0.74. The company has a current ratio of 1.88, a quick ratio of 1.62 and a debt-to-equity ratio of 1.13. Charles River Laboratories Intl. has a 52-week low of $86.25 and a 52-week high of $119.05.

CRL has been the subject of several recent research reports. Robert W. Baird set a $123.00 price objective on Charles River Laboratories Intl. and gave the company a “buy” rating in a research note on Tuesday. Argus assumed coverage on shares of Charles River Laboratories Intl. in a research report on Wednesday, December 13th. They set a “buy” rating and a $120.00 target price for the company. SunTrust Banks reissued a “buy” rating and set a $113.00 target price on shares of Charles River Laboratories Intl. in a research report on Friday, November 17th. Bank of America decreased their target price on shares of Charles River Laboratories Intl. from $117.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, November 10th. Finally, Zacks Investment Research raised shares of Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $129.00 target price for the company in a research report on Tuesday, October 24th. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $114.08.

In other Charles River Laboratories Intl. news, insider David Ross Smith sold 5,486 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $109.53, for a total transaction of $600,881.58. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Online Communications Bdirect sold 131,000 shares of the stock in a transaction that occurred on Thursday, January 18th. The stock was sold at an average price of $0.29, for a total value of $37,990.00. Insiders have sold a total of 195,673 shares of company stock valued at $2,644,046 in the last three months. Insiders own 2.20% of the company’s stock.

Several institutional investors have recently bought and sold shares of the business. Tocqueville Asset Management L.P. bought a new position in shares of Charles River Laboratories Intl. during the 4th quarter worth approximately $302,000. Renaissance Technologies LLC boosted its holdings in shares of Charles River Laboratories Intl. by 4.4% during the 4th quarter. Renaissance Technologies LLC now owns 1,398,700 shares of the medical research company’s stock worth $153,088,000 after buying an additional 58,991 shares in the last quarter. Koch Industries Inc. boosted its holdings in shares of Charles River Laboratories Intl. by 83.4% during the 4th quarter. Koch Industries Inc. now owns 5,622 shares of the medical research company’s stock worth $615,000 after buying an additional 2,556 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec bought a new position in shares of Charles River Laboratories Intl. during the 4th quarter worth approximately $4,378,000. Finally, ETRADE Capital Management LLC bought a new position in shares of Charles River Laboratories Intl. during the 4th quarter worth approximately $218,000. Hedge funds and other institutional investors own 97.13% of the company’s stock.

WARNING: This piece of content was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/13/charles-river-laboratories-intl-crl-posts-earnings-results-beats-expectations-by-0-14-eps.html.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Earnings History for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply